Cyclooxygenase-2 -1195G>A (rs689466) Polymorphism and Cancer Susceptibility: an Updated Meta-analysis Involving 50,672 Subjects

Overview

Journal Int J Clin Exp Med

Specialty General Medicine

Date 2015 Nov 10

PMID 26550156

Citations 5

Authors

Yafeng Wang

Heping Jiang

Tianyun Liu

Weifeng Tang

Zhiqiang Ma

Affiliations

Soon will be listed here.

Abstract

The association between cyclooxygenase-2 (COX-2) -1195G>A (rs689466) polymorphism and cancer risk has been extensively explored. However, the results of previous studies remain controversial. To address this gap, we performed an updated meta-analysis of fifty-eight studies involving a total of 50,672 subjects. Searching of PubMed and Embase databases was performed for publications on the association between COX-2 -1195G>A polymorphism and the risk of cancer. Statistical correlation was identified between COX-2 -1195G>A variants and overall cancer risk in five genetic models. In a sub-group analysis based on cancer type, significant association between COX-2 -1195G>A polymorphism and increased risk of gastric cancer, pancreatic cancer, hepatocellular carcinoma and other cancers was found. In a sub-group analysis by ethnicity, increased cancer risk was observed among Asians instead of Caucasians, Africans and mixed populations. Furthermore, in a sub-group analysis based on cancer system, increased cancer risk was found in digestive system cancer and other system cancer. Non-parametric "trim-and-fill" method was harnessed as a sensitivity analysis method and the results suggested our findings reliable. In summary, the results of our meta-analysis highlight that COX-2 -1195G>A polymorphism may be a risk factor for cancer.

Citing Articles

New Angiogenic Regulators Produced by TAMs: Perspective for Targeting Tumor Angiogenesis.

Larionova I, Kazakova E, Gerashchenko T, Kzhyshkowska J Cancers (Basel). 2021; 13(13).

PMID: 34209679 PMC: 8268686. DOI: 10.3390/cancers13133253.

Genetic Variations in Prostaglandin E Pathway Identified as Susceptibility Biomarkers for Gastric Cancer in an Intermediate Risk European Country.

Lopes C, Pereira C, Farinha M, Medeiros R, Dinis-Ribeiro M Int J Mol Sci. 2021; 22(2).

PMID: 33440718 PMC: 7827533. DOI: 10.3390/ijms22020648.

Cyclooxygenase-2 haplotypes influence the longitudinal risk of malaria and severe malarial anemia in Kenyan children from a holoendemic transmission region.

Anyona S, Hengartner N, Raballah E, Ongecha J, Lauve N, Cheng Q J Hum Genet. 2019; 65(2):99-113.

PMID: 31664161 PMC: 7255056. DOI: 10.1038/s10038-019-0692-3.

Non-random distribution of gastric cancer susceptible loci on human chromosomes.

Mahjoub G, Saadat M EXCLI J. 2018; 17:802-807.

PMID: 30233279 PMC: 6141820. DOI: 10.17179/excli2018-1425.

Genetic polymorphisms in very important pharmacogenomic variants in the Zhuang ethnic group of Southwestern China: A cohort study in the Zhuang population.

Li J, Guo C, Yan M, Niu F, Chen P, Li B Medicine (Baltimore). 2018; 97(17):e0559.

PMID: 29703042 PMC: 5944516. DOI: 10.1097/MD.0000000000010559.

References

Liang Y, Liu J, Wu Y, Zhang Z, Wu R . Cyclooxygenase-2 polymorphisms and susceptibility to esophageal cancer: a meta-analysis. Tohoku J Exp Med. 2011; 223(2):137-44. DOI: 10.1620/tjem.223.137. View

Nagao M, Sato Y, Yamauchi A . A meta-analysis of PTGS1 and PTGS2 polymorphisms and NSAID intake on the risk of developing cancer. PLoS One. 2013; 8(8):e71126. PMC: 3742790. DOI: 10.1371/journal.pone.0071126. View

Sugie S, Tsukino H, Mukai S, Akioka T, Shibata N, Nagano M . Cyclooxygenase 2 genotypes influence prostate cancer susceptibility in Japanese Men. Tumour Biol. 2013; 35(3):2717-21. DOI: 10.1007/s13277-013-1358-y. View

Tang Z, Nie Z, Pan Y, Zhang L, Gao L, Zhang Q . The Cox-2 -1195 G > A polymorphism and cancer risk: a meta-analysis of 25 case-control studies. Mutagenesis. 2011; 26(6):729-34. DOI: 10.1093/mutage/ger040. View

Gobel C, Breitenbuecher F, Kalkavan H, Hahnel P, Kasper S, Hoffarth S . Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunity. Cell Death Dis. 2014; 5:e1568. PMC: 4649842. DOI: 10.1038/cddis.2014.531. View

Vogel U, Christensen J, Wallin H, Friis S, Nexo B, Tjonneland A . Polymorphisms in COX-2, NSAID use and risk of basal cell carcinoma in a prospective study of Danes. Mutat Res. 2007; 617(1-2):138-46. DOI: 10.1016/j.mrfmmm.2007.01.005. View

Zhao D, Xu D, Zhang X, Wang L, Tan W, Guo Y . Interaction of cyclooxygenase-2 variants and smoking in pancreatic cancer: a possible role of nucleophosmin. Gastroenterology. 2009; 136(5):1659-68. DOI: 10.1053/j.gastro.2009.01.071. View

Moatter T, Aban M, Iqbal W, Pervez S . Cyclooxygenase-2 polymorphisms and breast cancer associated risk in Pakistani patients. Pathol Oncol Res. 2014; 21(1):97-101. DOI: 10.1007/s12253-014-9792-8. View

Bayram S, Akkiz H, Ulger Y, Bekar A, Akgollu E, Yildirim S . Lack of an association of programmed cell death-1 PD1.3 polymorphism with risk of hepatocellular carcinoma susceptibility in Turkish population: a case-control study. Gene. 2012; 511(2):308-13. DOI: 10.1016/j.gene.2012.09.119. View

10.

Srivastava K, Srivastava A, Pandey S, Kumar A, Mittal B . Functional polymorphisms of the cyclooxygenase (PTGS2) gene and risk for gallbladder cancer in a North Indian population. J Gastroenterol. 2009; 44(7):774-80. DOI: 10.1007/s00535-009-0071-5. View

11.

Hoff J, Te Morsche R, Roelofs H, van der Logt E, Nagengast F, Peters W . COX-2 polymorphisms -765G-->C and -1195A-->G and colorectal cancer risk. World J Gastroenterol. 2009; 15(36):4561-5. PMC: 2752001. DOI: 10.3748/wjg.15.4561. View

12.

Siemes C, Visser L, Coebergh J, Splinter T, Witteman J, Uitterlinden A . C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol. 2006; 24(33):5216-22. DOI: 10.1200/JCO.2006.07.1381. View

13.

Chang E, Birmann B, Kasperzyk J, Conti D, Kraft P, Ambinder R . Polymorphic variation in NFKB1 and other aspirin-related genes and risk of Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev. 2009; 18(3):976-86. PMC: 2720066. DOI: 10.1158/1055-9965.EPI-08-1130. View

14.

Andersen V, Holst R, Kopp T, Tjonneland A, Vogel U . Interactions between diet, lifestyle and IL10, IL1B, and PTGS2/COX-2 gene polymorphisms in relation to risk of colorectal cancer in a prospective Danish case-cohort study. PLoS One. 2013; 8(10):e78366. PMC: 3806836. DOI: 10.1371/journal.pone.0078366. View

15.

Deans C, Rose-Zerilli M, Wigmore S, Ross J, Howell M, Jackson A . Host cytokine genotype is related to adverse prognosis and systemic inflammation in gastro-oesophageal cancer. Ann Surg Oncol. 2006; 14(2):329-39. DOI: 10.1245/s10434-006-9122-9. View

16.

Kristinsson J, van Westerveld P, Te Morsche R, Roelofs H, Wobbes T, Witteman B . Cyclooxygenase-2 polymorphisms and the risk of esophageal adeno- or squamous cell carcinoma. World J Gastroenterol. 2009; 15(28):3493-7. PMC: 2715974. DOI: 10.3748/wjg.15.3493. View

17.

Mittal M, Kapoor V, Mohanti B, Das S . Functional variants of COX-2 and risk of tobacco-related oral squamous cell carcinoma in high-risk Asian Indians. Oral Oncol. 2010; 46(8):622-6. DOI: 10.1016/j.oraloncology.2010.06.002. View

18.

Thompson C, Plummer S, Merkulova A, Cheng I, Tucker T, Casey G . No association between cyclooxygenase-2 and uridine diphosphate glucuronosyltransferase 1A6 genetic polymorphisms and colon cancer risk. World J Gastroenterol. 2009; 15(18):2240-4. PMC: 2682239. DOI: 10.3748/wjg.15.2240. View

19.

Papafili A, Hill M, Brull D, McAnulty R, Marshall R, Humphries S . Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol. 2002; 22(10):1631-6. DOI: 10.1161/01.atv.0000030340.80207.c5. View

20.

Chang W, Yang M, Tsai C, Cheng L, Jeng L, Lo W . Association of cyclooxygenase 2 single-nucleotide polymorphisms and hepatocellular carcinoma in Taiwan. Chin J Physiol. 2012; 55(1):1-7. DOI: 10.4077/CJP.2012.AMM056. View